Fundraising Fox

Third Pole

Waltham, US · Founded 2014 · Delaware corporation · 1 known investors

pole3.com ↗

Third Pole Therapeutics develops a tankless, wearable inhaled nitric oxide (iNO) delivery platform, including the portable eNOfit device that generates nitric oxide on demand rather than storing it in tanks. The company operates in the biotech and medical device space, developing its technology through clinical feasibility studies for patient care.

BiotechHealthtechMedical Devices

Founders & leadership

DZ
David ZapolDirector
EH
Elizabeth HolmbergCFO and Treasurer
BA
Basil AthensonChief Executive Officer and President
AP
Ashleigh PalmerDirector
JM
Jeffrey McCormickDirector
WC
Werner CautreelsDirector
RR
Ron RobisonDirector
WH
William HeidenDirector
HP
Hirak ParikhDirector
EL
Emily Ladd-KravitzSecretary

Investors · 1

Saturn PartnersBoston

Competitors · 4

by search overlap
Concord Communications10 shared keywords
Cowles_Investments_StemCentrx9 shared keywordsFierce Biotech is a news publication covering the biotechnology, pharmaceutical, and medtech industries, reporting on clinical trials, deals, venture capital, drug development, and research. It serves industry professionals through articles, special reports, events, webinars, and podcasts.
Mapquest8 shared keywordsProvider of geographical information systems and services; acquired by America Online.
Loopnet7 shared keywords

Companies competing with Third Pole for the same Google search keywords, organic and paid, via search-intersection analysis.

Reported raises · per SEC filings

Form D private placements
▶$16.9MraisedMar 2025 · 22 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Werner CautreelsDirector
  • David ZapolDirector
  • Emily Ladd-KravitzExecutive Officer
  • Elizabeth HolmbergExecutive Officer
  • Jeffrey McCormickDirector
  • Ron RobisonDirector
  • William HeidenDirector
  • Hirak ParikhDirector
  • Basil AthensonDirector, Executive Officer
Offering amount
$30M
Amount sold
$16.9M
Placement agents
Saturn Capital, Inc.
First sale
Mar 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$55.2MraisedFeb 2024 · 85 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Basil AthensonDirector, Executive Officer
  • Matthew GaylordDirector
  • Emily Ladd-KravitzExecutive Officer
  • Ron RobisonDirector
  • Elizabeth HolmbergExecutive Officer
  • Jeffrey McCormickDirector
  • Werner CautreelsDirector
  • William HeidenDirector
Amount sold
$55.2M
Placement agents
Saturn Capital, Inc.
First sale
Mar 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$13.8MraisedJan 2018 · 49 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ashleigh PalmerDirector
  • David ZapolExecutive Officer, Director, Promoter
  • Jeffrey McCormickDirector
Offering amount
$14M
Amount sold
$13.8M
Minimum investment
$15K
Sales commissions
$1.1M
Proceeds to insiders
$426K
Placement agents
Saturn Capital, Inc.
First sale
Dec 2015
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2021$1.8M
National Institutes of Health (NIH)National Institutes of HealthPhase II2019$3M
National Institutes of Health (NIH)National Institutes of HealthPhase II2016$2M
National Institutes of Health (NIH)National Institutes of HealthPhase II2016$1.5M

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.